Startups
Adalvo
Edit

Adalvo

Trusted
http://www.adalvo.com/
Last activity: 09.06.2026
Active
Categories: B2BBusinessCommerceDevelopmentGrowthLocalMedtechProductServiceSmart
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 70 countries and for over 90 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners. With headquarters in Malta, the company has additional offices in more than 15 countries such as Switzerland, UK, Netherlands, Spain, Iceland, Austria, Romania, Hungary, Bulgaria, Portugal, Czech Republic, and India. At Adalvo, we know that our partners like to be bigger, better and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals. We take pride in our ability to help its partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion to making a difference for partners. The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
Followers
20.97K
Mentions
5

Overview

Location
Malta, Central Region, Saint John
Employees
201-500
Founded date
2020

Mentions in press and media 5

DateTitleDescription
Sign up to seeSign up to seeSign up to see
Jul 18, 2025EQT to acquire Adalvo, a leading B2B dossier developerEQT to acquire Adalvo, a leading B2B dossier developer Fri, Jul 18, 2025 10:00 CET Report this content EQT X to acquire Adalvo, a rapidly growing, asset-light B2B dossier developer providing market-approval-ready generic drug dossiers to ph...
May 28, 2025Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and PainTAIPEI, May 28, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Adalvo Limited ("Adalvo") in the European a...
Jan 11, 2023Adalvo and STADA extend their strategic partnershipSTADA has extended its strategic partnership with Adalvo Strategic partnership in Europe extended to cover five additional molecules in therapeutic categories including oncology and diabetes Working closely as a trusted partner with Adalvo ...
May 10, 2022Robert Wessman-led Aztiq completes $500 million transaction in an alliance with Innobic to create an international pharma powerhouseThe Consortium jointly, through Aztiq II HoldCo, has completed the acquisition of a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus Pharmaceuticals and Adalvo Róbert Wessman, Chair...

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about Adalvo

When was Adalvo founded?

Adalvo was founded in 2020.

What has the press written about Adalvo?

Parsers VC has collected 5 articles mentioning Adalvo, among them “EQT to acquire Adalvo, a leading B2B dossier developer” (Jul 18, 2025) and “Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammat...” (May 28, 2025).

Is Adalvo still active?

Yes, Adalvo is active; its latest activity on Parsers VC dates from Jun 9, 2026.